New hope to stop deadly Post-Transplant virus
NCT ID NCT07261215
Summary
This study is testing a new drug called zuberitamab to see if it can safely and effectively treat early signs of Epstein-Barr virus (EBV) infection in adults who have recently received a donor stem cell transplant. The goal is to prevent the virus from causing a serious, often fatal complication called post-transplant lymphoproliferative disorder. Researchers will compare this new drug to the current standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HSCT are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.